Voyager Therapeutics Inc (VYGR)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $107.66M
Last updated: Nov 17, 2026 at 4:38 PM ET
Voyager Therapeutics Inc (VYGR) Statistics
Voyager Therapeutics (VYGR) has a market cap of $107.66M and an enterprise value of $59.25M. It kept -416.32% of revenue as net income over the last 12 months. It holds $48.41M more cash than debt, 44.97% of its market cap.
Total Valuation
Enterprise value is 44.97% below the market cap, as cash exceeds debt.
| Market Cap | $107.66M |
|---|---|
| Enterprise Value | $59.25M |
| Latest price (Nov 17, 2026) | $1.52 |
Key Dates
The next earnings report is expected on Mar 8, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Mar 8, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 5, 2026 |
| Fiscal Year End | December |
Valuation Ratios
Sales and book value multiples are 3.7x and 0.7x. Its year-end P/S ranged from 1.4x to 45.8x from 2016 to 2025.
| P/S Ratio | 3.7x |
|---|---|
| Forward P/S | 7.0x |
| P/B Ratio | 0.7x |
Price Statistics
The stock is down 61.32% over 52 weeks and trades 34.20% below its 50-day average.
| Beta (1Y) | 1.52 |
|---|---|
| 52-Week Change | -61.32% |
| 1-Month Change | -25.85% |
| 3-Month Change | -55.43% |
| 6-Month Change | -56.32% |
| 5-Year Change | -52.49% |
| 10-Year Change | -85.67% |
| Total Return (1Y) | -61.32% |
| Total Return (3Y CAGR) | -39.36% |
| Total Return (5Y CAGR) | -13.63% |
| Return vs SPY (1Y) | -76.05% |
| Max Drawdown (1Y) | -69.60% |
| Max Drawdown (3Y) | -85.98% |
| Sharpe Ratio (1Y) | -1.70 |
| Correlation with SPY (1Y) | 0.34 |
| 50-Day Average | $2.31 |
| 200-Day Average | $3.33 |
| 52-Week Range | $1.59 to $5.48 |
| RSI (14 Days) | 32.6 |
| Average Volume (20 Days) | 1.04M |
The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 6.81x current liabilities, and total debt is 0.00x shareholder equity.
| Current Ratio | 6.81x |
|---|---|
| Quick Ratio | 6.81x |
| Debt / Equity | 0.00x |
Returns and Efficiency
Return on equity is -77.37% over the last 12 months, against a 5-year average of -36.06%.
| Return on Equity (ROE) | -77.37% |
|---|---|
| Return on Assets (ROA) | -59.04% |
| ROE (5Y Average) | -36.06% |
| ROA (5Y Average) | -18.43% |
| ROIC (5Y Average) | -66.40% |
| Asset Turnover | 0.11x |
| Receivables Turnover | 7.23x |
Scores
VYGR has an Altman Z-Score of -4.06, in the distress zone below 1.81, and a Piotroski F-Score of 1 of 9, in the weak band of 0 to 2.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | -4.06 |
|---|---|
| Altman Z Zone | Distress |
| Piotroski F-Score | 1 of 9 |
| Piotroski Strength | Weak |
Income Statement
Revenue of $25.11M over the last 12 months is down 19.82% from the 12 months before.
| Revenue | $25.11M |
|---|---|
| Revenue Growth (YoY) | -19.82% |
| Gross Profit | $25.11M |
| Operating Income | -$113.02M |
| Pretax Income | -$104.47M |
| Net Income | -$104.53M |
| Reported EPS (TTM) | -$1.74 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 76.31% of the $177.05M in total assets.
| Cash and Equivalents | $48.41M |
|---|---|
| Total Debt | $0 |
| Net Cash | $48.41M |
| Net Cash Per Share | $0.78 |
| Working Capital | $97.62M |
| Shareholder Equity | $135.11M |
| Book Value Per Share | $2.19 |
| Total Assets | $177.05M |
| Total Liabilities | $41.94M |
Balance sheet as of Sep 30, 2026.
Cash Flow
| Operating Cash Flow | -$109.19M |
|---|---|
| FCF Per Share | -$1.78 |
| Depreciation and Amortization | $5.00M |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is -450.12%.
| Gross Margin | 100.00% |
|---|---|
| Operating Margin | -450.12% |
| Pretax Margin | -416.08% |
| Net Margin | -416.32% |
Growth
Revenue fell 0.44% a year over 3 years.
| Revenue Growth (3Y CAGR) | -0.44% |
|---|---|
| Revenue Growth (5Y CAGR) | -25.09% |
| Book Value Per Share Growth (2Y CAGR) | -20.17% |
| Tangible Book Per Share Growth (2Y CAGR) | -20.17% |
Dividends and Yields
VYGR does not pay a dividend.
| Buyback Yield | -9.61% |
|---|---|
| Shareholder Yield | -9.61% |
Analyst Forecast
Consensus estimates put revenue growth at 5.27% a year over the next 2 fiscal years.
| Revenue Growth Forecast (2Y CAGR) | +5.27% |
|---|
Price Target
Analyst price targets are part of paid GNG plans. See plans
GNG Valuation
| GNG view | Undervalued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About VYGR
What is VYGR's market cap?
Voyager Therapeutics has a market cap of $107.66M. Its enterprise value, which adds debt and subtracts cash, is $59.25M.
How many shares of VYGR are outstanding?
Voyager Therapeutics has 61.82M shares outstanding. The count is up 5.14% from a year earlier.
Does VYGR pay a dividend?
No. Voyager Therapeutics does not pay a dividend.
How much debt does VYGR have?
Voyager Therapeutics has $0 of total debt and $48.41M of cash and equivalents, a net cash position of $48.41M.
VYGR pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors